FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084544484> ?p ?o ?g. }

• W2084544484 endingPage "94" @default.
• W2084544484 startingPage "68" @default.
• W2084544484 abstract "CA: A Cancer Journal for CliniciansVolume 38, Issue 2 p. 68-94 FeatureFree Access The immunologic treatment of cancer Michael T. Lotze MD, Michael T. Lotze MD Senior Investigator in the Surgery Branch, Tumor Immunology Section, of the National Cancer Institute in Bethesda, MarylandSearch for more papers by this authorSteven A. Rosenberg MD, PhD, Steven A. Rosenberg MD, PhD Chief of the Surgery Branch of the National Cancer Institute in Bethesda, MarylandSearch for more papers by this author Michael T. Lotze MD, Michael T. Lotze MD Senior Investigator in the Surgery Branch, Tumor Immunology Section, of the National Cancer Institute in Bethesda, MarylandSearch for more papers by this authorSteven A. Rosenberg MD, PhD, Steven A. Rosenberg MD, PhD Chief of the Surgery Branch of the National Cancer Institute in Bethesda, MarylandSearch for more papers by this author First published: March/April 1988 https://doi.org/10.3322/canjclin.38.2.68Citations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 WD Terry, SA Rosenberg (eds): Immunotherapy of Human Cancer. New York, Elsevier, 1982. 2 Oldham RK: Biological response modifiers. JNCI 70: 789– 796, 1983. 3 Rosenberg SA, Rapp HJ: Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60: 419– 430, 1976. 4 Eilber FR, Morton DL, Holmes EC, et al: Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med 294: 237– 240, 1976. 5 Veronesi V, Adamus J, Aubert C, et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913– 916, 1982. 6 Mastrangelo MJ, Berd D, Maguire HC Jr: Current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat Rep 68: 207– 219, 1984. 7 Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495– 497, 1975. 8 Miller RA, Maloney DG, Warnke R, et al: Treatment of β-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 306: 517– 522, 1982. 9 Miller RA, Maloney DG, McKillop J, et al: In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 78– 86, 1981. 10 Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399– 406, 1980. 11 Merigan TC, Sikora K, Breeden JH, et al: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299: 1449– 1453, 1978. 12 Horning SJ, Levine JF, Miller RA, et al: Clinical and immunological effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 247: 1718– 1722, 1982. 13 Grunberg SM, Kempf RA, Venturi CL, et al: Phase I study of recombinant β-interferon given by four-hour infusion. Cancer Res 47: 1174– 1178, 1987. 14 Kurzrock R, Rosenblum MG, Sherwin SA, et al: Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45: 2866– 2872, 1985. 15 Lotze MT, Matory YL, Ettinghausen SE, et al: In vivo administration of purified human interleukin 2: II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865– 2875, 1985. 16 Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316: 379– 385, 1987. 17 Lotze MT, Rosenberg SA: Protocol design for lymphokine testing in clinical studies of human cancer. Lymphokine Res 5: S177– S182, 1986. 18 Merigan TC: Interferon—the first quarter century. JAMA 248: 2513– 2516, 1982. 19 Lotze MT, Rosenberg SA: In vivo use of cytokines. Clin Immunol Newsletter 5: 116– 120, 1984. 20 Shu S, Chou T, Rosenberg SA: In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res 47: 1354– 1360, 1987. 21 Rosenberg SA, Eberlein TJ, Grimm EA, et al: Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: A new approach to the adoptive immunotherapy of cancer. Surgery 92: 328– 336, 1982. 22 Morton DL: Active immunotherapy against cancer: Present status. Semin Oncol 13: 180– 185, 1986. 23 Hoover HC Jr, Surdyke MG, Dangel RB, et al: Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236– 1243, 1985. 24 Livingston PO, Albino AP, Chung TJ, et al: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55: 713– 720, 1985. 25 O'Donnell RW, Marquis DM, Mudholkar GS, et al: In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines. Cancer Res 46: 3273– 3278, 1986. 26 Koprowski H, Herlyn D, Lubeck M, et al: Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 81: 216– 219, 1984. 27 Morales A, Eidinger D, Bruce AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180– 183, 1976. 28 Lamon DL, Thor DE, Stogdill VD, et al: Bladder cancer immunotherapy. J Urol 128: 931– 935, 1982. 29 Ishida N, Hoshino J: A streptococcal preparation as a potent biological response modifier, OK-432. Tokyo, Excerpta Medica, 1985. 30 Izawa M-A, Ohno K, Amikura K, et al: Lentinan augments the production of interleukin 3 and colony stimulating factor(s) by T cells, in J Aoki, E Tsubura, I Urushizaki (eds): Manipulation of Host Defence Mechanism. Tokyo, Excerpta Medica, 1983, pp 59– 69. 31 Chirigos MA, Mastrangelo MJ: Immunorestoration by chemicals, in E Mihich (ed): Immunological Approaches to Cancer Therapeutics. New York, John Wiley & Sons, Inc., 1982, pp 191– 239. 32 Bicker U: Aziridine dyes: Preclinical and clinical studies, in EM Hersh, MA Chirigos, MJ Mastrangelo (eds): Progress in Cancer Research and Therapy. Vol 16, Augmenting Agents in Cancer Therapy. New York, Raven Press, 1981, pp 523– 537. 33 Symoens J, Rosenthal M, DeBrabander M, et al: Immunoregulation with levamisole, in L Chedid, PA Miescher, HJ Mueller-Eberhard (eds): Immunostimulation. Berlin, Springer-Verlag, 1980, pp 195– 214. 34 Hadden JW, Giner-Sorolla A: Isoprinosine and NPT 15392: Modulators of lymphocyte and macrophage development and function, in EM Hersh, MA Chirigos, MJ Mastrangelo (eds): Progress in Cancer Research and Therapy. Vol 16, Augmenting Agents in Cancer Therapy. New York, Raven Press, 1981, pp 497– 522. 35 Lotze MT: Treatment of immunologic disorders in AIDS, in VT DeVita, S Hellman, SA Rosenberg (eds): AIDS: Etiology, Diagnosis, Treatment, and Prevention. Philadelphia, JB Lippincott, 1985, pp 235– 264. 36 Hengst JCD, Kempf RA: Immunomodulation by cyclophosphamide, in MS Mitchell, JL Fahey (eds): Clinics in Immunology and Allergy. Vol 4, Immune Suppression and Modulation. London, WB Saunders, 1984, pp 199– 216. 37 Ozer H: Effects of alkylating agents on immunoregulatory mechanisms, in E Mihich, Y Sakurai (eds): Biological Responses in Cancer. Vol 3, Immunomodulations by Anticancer Drugs. New York, Plenum Press, 1985, pp 95– 130. 38 Ehrke MJ, Mihich E: Adriamycin and other anthracyclines, in MS Mitchell, JL Fahey (eds): Clinics in Immunology and Allergy. Vol 4, Immune Suppression and Modulation. London, WB Saunders, 1984, pp 259– 277. 39 Mastrangelo MJ, Berd D, Maguire H Jr: The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol 13: 186– 194, 1986. 40 Gutterman JU, Fein S, Quesada J, et al: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96: 549– 556, 1982. 41 Talpaz M, McCredie KB, Mavligit GM, et al: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogeneous leukemia. Blood 62: 689– 692, 1983. 42 Bergsagel DE, Haas RH, Messner HA: Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13: 29– 34, 1986. 43 Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310: 15– 18, 1984. 44 Groopman JE: Therapeutic options in hairy-cell leukemia. Semin Oncol 12: 30– 34, 1985. 45 Volberding PA, Mitsuyasu R: Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol 12: 2– 6, 1985. 46 Canellos GP: Interferon in the treatment of malignant lymphoma. Semin Oncol 12: 25– 29, 1985. 47 Foon KA, Roth MS, Bunn PA Jr: Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol 13: 35– 42, 1986. 48 Bunn PA Jr, Foon KA: Therapeutic options in advanced cutaneous T cell lymphomas: A role for interferon alpha-2a (Roferon-A). Semin Oncol 12: 18– 24, 1985. 49 Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12: 7– 12, 1985. 50 Kirkwood JM, Ernstoff M: Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma. Semin Oncol 13: 48– 56, 1986. 51 Cooper MR, Welander CE: Interferons in the treatment of multiple myeloma. Semin Oncol 13: 334– 340, 1986. 52 Cooper MR: Interferons in the treatment of multiple myeloma. Semin Oncol 13: 13– 20, 1986. 53 Quesada JR, Swanson DA, Trindade A, et al: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43: 940– 947, 1983. 54 Krown SE: Therapeutic options in renal-cell carcinoma. Semin Oncol 12: 13– 17, 1985. 55 Gedell DV, Kleid DG, Bolivar F, et al: Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76: 106– 110, 1979. 56 Howe PD, Marin ND, Hutchinson AS, et al: A fifteen month double blind crossover study of the efficacy and antigenicity of human and pork insulins. Diabetes Medicine 1: 93– 98, 1984. 57 Gutterman JU, Rosenblum MG, Rios A, et al: Pharmacokinetic study of partially pure gamma-interferon in cancer patients. Cancer Res 44: 4164– 4171, 1984. 57a Ernstoff MS, Trautman T, Davis CA, et al: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5: 1804– 1810, 1987. 58 Van DeWerl F, Vonbaecke J, de Geest H, et al: Coronary thrombolysis with recombinant single chain urolanase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74: 1066– 1070, 1986. 59 Verstraete M, Bernard R, Bory M, et al: Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1: 842– 847, 1985. 60 Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. New Engl J Med 316: 73– 78, 1987. 61 Asher A, Mulé JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963– 974, 1987. 61a Groopman JE, Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant human granulocytemacrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317: 593– 598, 1987. 61b Guler H-P, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137– 140, 1987. 62 Kurzrock R, Quesada JR, Talpaz M, et al: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 4: 1101– 1109, 1985. 63 Nathan CF, Horowitz CR, De la Harpe J, et al: Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82: 8686– 8690, 1985. 64 Kurzrock R, Rohde MF, Quesada JR, et al: Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 164: 1093– 1101, 1986. 65 Pfizenmaier K, Scheurich P, Schlüter C, et al: Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol 138: 975– 980, 1987. 66 Bindon C, Czerniecki M, Ruell P, et al: Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123– 133, 1983. 67 Lotze MT, Frana LW, Sharrow SO, et al: In vivo administration of purified human interleukin 2: 1. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134: 157– 166, 1985. 68 Lotze MT, Line BT, Mathisen DJ, et al: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 125: 1487– 1493, 1980. 69 Lotze MT, Grimm EA, Mazumder A, et al: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF). Cancer Res 41: 4420– 4425, 1981. 70 Grimm EA, Robb RJ, Roth JA, et al: Lymphokine-activated killer cell phenomenon: III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158: 1356– 1361, 1983. 71 Perez P, Titus JA, Lotze MT, et al: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 137: 2069– 2072, 1986. 72 Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485– 1492, 1985. 73 Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immuno-therapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318– 1321, 1986. 74 Eisenthal A, Lafreniere R, Lefor AT, et al: Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 2771– 2776, 1987. 75 Cohen PJ, Lotze MT, Roberts JR, et al: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: Correlation of response with T-cell infiltration and HLA-DR expression. Amer J Pathol 129: 208– 216, 1987. 76 Cotran R, Lotze MT, Wiebke EA, et al: Endothelial activation during interleukin-2 (IL-2) immunotherapy: A possible mechanism for the vascular leak syndrome. J Immunol, 1988, in press. 77 Mulé JJ, Shu S, Schwarz SL, et al: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 255: 1487– 1489, 1984. 78 Lafreniere R, Rosenberg SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735– 3741, 1985. 79 Rosenberg SA, Mulé JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169– 1188, 1985. 80 Mulé JJ, Yang JC, Lafreniere R, et al: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139: 285– 294, 1987. 81 Lotze MT, Custer MC, Sharrow SO, et al: In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following IL-2 administration. Cancer Res 47: 2188– 2195, 1987. 82 Lotze MT, Matory YL, Rayner AA, et al: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 194– 202, 1986. 83 Rosenberg SA, Lotze MT: Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4: 681– 709, 1986. 84 Rosenberg SA, Lotze MT, Muul LM, et al: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100: 262– 272, 1986. 85 Lotze MT, Rosenberg SA: Interleukin-2 as a pharmacologic reagent, in K Smith (ed): Lymphokines. New York, Academic Press, in press, 1987. 86 Cohen PJ, Lotze MT, Roberts JR, et al: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T cell infiltration and HLA-DR expression. Amer J Pathol 129: 208– 216, 1987. 87 Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889– 897, 1987. 88 Lotze MT, Chang AE, Seipp CA, et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117– 3124, 1986. 89 Munck A, Guyre PM, Holbrook NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5: 25– 44, 1984. 90 Vetto JT, Papa MZ, Lotze MT, et al: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroid. J Clin Oncol 5: 496– 503, 1987. 91 Nieman LK, Choate TM, Chrousos GP, et al: The progesterone antagonist RU 486: A potential new contraceptive agent. New Engl J Med 316: 187– 191, 1987. 92 Rosenberg SA, Terry WD: Passive immunotherapy of cancer in animals and man, in G Klein, S Weinhouse (eds): Advances in Cancer Research, vol 25. New York, Academic Press, 1977, pp 323– 388. 93 Order SE, Stillwagon GB, Klein JL, et al: Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3: 1573– 1582, 1985. 94 Tomita S, Lotze MT, Rosenberg SA: Clonal analysis of tumor infiltrating lymphocytes against human malignant melanoma. Fed Proc 46: 1195, 1987. 95 MS Mitchell, HF Oettgen (eds): Progress in Cancer Research and Therapy. Vol 21, Hybridomas in Cancer Diagnosis and Treatment. New York, Raven Press, 1982. 96 Schlom J: Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 46: 3225– 3238, 1986. 97 Haspel MV, McCabe RP, Pomato N, et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45: 3951– 3961, 1985. 98 Liu AY, Robinson RR, Hellström KE, et al: Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci 84: 3439– 3443, 1987. 99 Hellström I, Garrigues HJ, Cabasco L, et al: Studies of a high molecular weight human melanoma-associated antigen. J Immunol 130: 1467– 1472, 1983. 100 Hellström I, Brankovan V, Hellström KE: Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82: 1499– 1502, 1985. 101 Johnson VG, Schlom J, Paterson AJ, et al: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46: 850– 857, 1986. 102 Muraro R, Wunderlich D, Thor A, et al: Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 45: 5769– 5780, 1985. 103 Fargion S, Carney D, Mulshine J, et al: Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 46: 2633– 2638, 1986. 104 Hellström I, Horn D, Linsley P, et al: Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 46: 3917– 3923, 1986. 105 Lotze MT, Carrasquillo JA, Weinstein JN, et al: Monoclonal antibody imaging of human melanoma: Radioimmunodetection by subcutaneous or systemic injection. Ann Surg 204: 223– 235, 1986. 106 Carrasquillo JA, Bunn PA Jr, Keenan AM, et al: Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med 315: 673– 680, 1986. 107 Engelstad BL, Spitler LE, Del Rio MJ, et al: Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody. Radiology 161: 419– 422, 1986. 108 Weinstein JN, Steller MA, Covell DG, et al: Monoclonal antitumor antibodies in the lymphatics. Cancer Treat Rep 68: 257– 264, 1984. 109 Scheinberg DA, Strand M, Gansow OA: Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 215: 1511– 1513, 1982. 110 Brown JP, Woodbury RG, Hart CE, et al: Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78: 539– 543, 1981. 111 Schulz G, Bumol TF, Reisfeld RA: Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 80: 5407– 5411, 1983. 112 Schulz G, Staffileno LK, Reisfeld RA, et al: Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 161: 1315– 1325, 1985. 113 Shiloni E, Eisenthal A, Sachs D, et al: Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138: 1992– 1998, 1987. 114 Honsik CJ, Jung G, Reisfeld RA: Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 83: 7893– 7897, 1986. 115 Karpovsky B, Titus JA, Stephany DA, et al: Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med 160: 1686– 1701, 1984. 116 Lotze MT, Roberts K, Custer MC, et al: Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: A possible approach to the immunotherapy of human tumors. J Surg Res 42: 580– 589, 1987. 116a Titus JA, Perez P, Kaubisch A, et al: Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 139: 3153– 3158, 1987. 117 Redwood WR, Tom TD, Strand M: Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res 44: 5681– 5687, 1984. 118 Gilliland DG, Steplewski Z, Collier RJ, et al: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77: 4539– 4543, 1980. 119 Houston LL, Nowinski RC: Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against thy 1.1 antigen. Cancer Res 41: 3913– 3917, 1981. 120 Blythman HE, Casellas P, Gros O, et al: Immunotoxins: Hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells. Nature 290: 145– 146, 1981. 121 Vitetta ES, Krolick KA, Uhr JW: Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev 62: 159– 183, 1982. 122 Thorpe PE, Ross WC: The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62: 119– 158, 1982. 123 Spitler LE, del Rio M, Khentigan A, et al: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47: 1717– 1723, 1987. 124 Pimm MV, Jones JA, Price MR, et al: Tumour localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumour growth with adriamycin-antibody conjugates. Cancer Immunol Immunother 12: 125– 134, 1982. 125 Baldwin RW, Embleton MJ, Pimm MV: Application of tumor-localizing 791T/36 monoclonal antibody in radioimmunodetection of experimental and human tumors and targeting cytotoxic drugs such as vindesine and methotrexate, in BD Boss, R Langman, I Trowbridge, et al (eds): Monoclonal Antibodies and Cancer. Orlando, Fla, Academic Press, Inc, 1983, pp 265– 274. 126 Endo N, Kato Y, Takeda Y, et al: In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Res 47: 1076– 1080, 1987. 127 Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2: 226– 230, 1981. 128 Sears HF, Herlyn D, Steplewski E, et al: Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 3: 138– 150, 1984. 129 Sindelar WF, Maher MM, Herlyn D, et al: Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: Preliminary results. Hybridoma 5: S125– S132, 1986. 130 Goodman GE, Beaumier P, Hellström I, et al: Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3: 340– 352, 1985. 131 Houghton AN, Mintzer D, Corden-Cardo C, et al: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242– 1246, 1985. 131a Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83: 8694– 8698, 1986. 131b Cheung N-KV, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430– 1440, 1987. 132 Skibber JM, Lotze MT, Muul LM, et al: Isolation of the human lymphokine activated killer characterization of the precursor and effector cell. Natural Immunology and Cell Growth Regulation, in press, 1987. 133 Roberts K, Lotze MT, Rosenberg SA: Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 47: 4366– 4371, 1987. 134 Roberts K, Lotze MT, Rosenberg SA: Interleukin 2 (IL-2) promotes conjugate formation by purified lymphokine activated killer (LAK) precursors and T lymphocytes: Enumeration of cell conjugates by flow cytometry. J Biol Response Mod, in press. 135 Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2, in VT DeVita, S Hellman, SA Rosenberg (eds): Important Advances in Oncology 1986. Philadelphia, JB Lippincott, 1986, pp 55– 91. 136 A Fefer, AL Goldstein (eds): Progress in cancer research and therapy. Vol 22, The Potential Role of T Cells in Cancer Therapy. New York, Raven Press, 1982. 137 Muul LM, Spiess PJ, Director EP, et al: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989– 995, 1987. 137a Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. Submitted for publication, 1988. 138 Lotze MT, Custer MC, Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121: 1373– 1379, 1986. 139 Papa MZ, Vetto JT, Shiloni E, et al: Synergistic effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Submitted, J Natl Cancer Inst, 1987. 140 Mulé JJ, Smith CA, Rosenberg SA: Interleukin-4 (B-cell stimulatory factor-1) can mediate the induction of LAK activity directed against fresh tumor cells. J Exp Med 166: 792– 797, 1987. 140a Kawakami Y, Custer M, Rosenberg SA, et al: Human interleukin 4 (IL4) inhibits interleukin 2 (IL2) induction of human lymphokine activated killer (LAK) activity from peripheral blood and spleen cells. Fed Proc, in press, 1988. Citing Literature Volume38, Issue2March/April 1988Pages 68-94 ReferencesRelatedInformation" @default.
• W2084544484 created "2016-06-24" @default.
• W2084544484 creator A5024528047 @default.
• W2084544484 creator A5072133376 @default.
• W2084544484 date "1988-03-01" @default.
• W2084544484 modified "2023-10-16" @default.
• W2084544484 title "The Immunologic Treatment Of Cancer" @default.
• W2084544484 cites W11928235 @default.
• W2084544484 cites W1483963831 @default.
• W2084544484 cites W1489541744 @default.
• W2084544484 cites W1497377046 @default.
• W2084544484 cites W1504458230 @default.
• W2084544484 cites W1507938174 @default.
• W2084544484 cites W1521509742 @default.
• W2084544484 cites W1521983457 @default.
• W2084544484 cites W1530174196 @default.
• W2084544484 cites W1555460822 @default.
• W2084544484 cites W1562381562 @default.
• W2084544484 cites W1576018417 @default.
• W2084544484 cites W1576953154 @default.
• W2084544484 cites W1590924395 @default.
• W2084544484 cites W1600577617 @default.
• W2084544484 cites W1606300676 @default.
• W2084544484 cites W1643040145 @default.
• W2084544484 cites W1645358757 @default.
• W2084544484 cites W1654548623 @default.
• W2084544484 cites W1759213026 @default.
• W2084544484 cites W1783973309 @default.
• W2084544484 cites W1813204405 @default.
• W2084544484 cites W1826412460 @default.
• W2084544484 cites W1890985457 @default.
• W2084544484 cites W1891234789 @default.
• W2084544484 cites W1907323769 @default.
• W2084544484 cites W1916563986 @default.
• W2084544484 cites W1951179504 @default.
• W2084544484 cites W1951776719 @default.
• W2084544484 cites W1965304265 @default.
• W2084544484 cites W1965861552 @default.
• W2084544484 cites W1969410654 @default.
• W2084544484 cites W1975386114 @default.
• W2084544484 cites W1977096306 @default.
• W2084544484 cites W1977476969 @default.
• W2084544484 cites W1978482821 @default.
• W2084544484 cites W1979772679 @default.
• W2084544484 cites W1980123039 @default.
• W2084544484 cites W1985981664 @default.
• W2084544484 cites W1994911302 @default.
• W2084544484 cites W1995628336 @default.
• W2084544484 cites W1997309117 @default.
• W2084544484 cites W2014113952 @default.
• W2084544484 cites W2015139192 @default.
• W2084544484 cites W2016292927 @default.
• W2084544484 cites W2021977722 @default.
• W2084544484 cites W2023356979 @default.
• W2084544484 cites W2028697515 @default.
• W2084544484 cites W2030522563 @default.
• W2084544484 cites W2035097199 @default.
• W2084544484 cites W2041614988 @default.
• W2084544484 cites W2042301343 @default.
• W2084544484 cites W2043008373 @default.
• W2084544484 cites W2043133764 @default.
• W2084544484 cites W2043460390 @default.
• W2084544484 cites W2048540725 @default.
• W2084544484 cites W2049822454 @default.
• W2084544484 cites W2051032788 @default.
• W2084544484 cites W2051243855 @default.
• W2084544484 cites W2052175782 @default.
• W2084544484 cites W2056386474 @default.
• W2084544484 cites W2057058036 @default.
• W2084544484 cites W2058331779 @default.
• W2084544484 cites W2068392981 @default.
• W2084544484 cites W2068441417 @default.
• W2084544484 cites W2076651926 @default.
• W2084544484 cites W2078635736 @default.
• W2084544484 cites W2080484471 @default.
• W2084544484 cites W2081059129 @default.
• W2084544484 cites W2081096579 @default.
• W2084544484 cites W2085414514 @default.
• W2084544484 cites W2087947855 @default.
• W2084544484 cites W2088283955 @default.
• W2084544484 cites W2089828715 @default.
• W2084544484 cites W20902126 @default.
• W2084544484 cites W2096574716 @default.
• W2084544484 cites W2104670043 @default.
• W2084544484 cites W2105566826 @default.
• W2084544484 cites W2108635678 @default.
• W2084544484 cites W2113973363 @default.
• W2084544484 cites W2114921925 @default.
• W2084544484 cites W2117925216 @default.
• W2084544484 cites W2128087377 @default.
• W2084544484 cites W2128394628 @default.
• W2084544484 cites W2129415266 @default.
• W2084544484 cites W2130537353 @default.
• W2084544484 cites W2130805522 @default.
• W2084544484 cites W2130946928 @default.
• W2084544484 cites W2141298931 @default.
• W2084544484 cites W2144360148 @default.
• W2084544484 cites W2149802496 @default.

• next